The Food and Drug Administration on Monday approved the first oral medication to treat obesity, clearing a once-daily pill after clinical trials showed significant weight loss and cardiovascular benefit, drugmaker Novo Nordisk said.
The Wegovy pill contains semaglutide, the same active ingredient used in the company’s injectable Wegovy and Ozempic products. It is the first oral GLP-1 receptor agonist approved in the U.S. for chronic weight management.
The FDA approved the pill for adults with obesity, or those who are overweight with at least one weight-related condition, such as heart disease, when used alongside diet and exercise.
Read more at Newsmax© 2025 Newsmax. All rights reserved.
